Pharmaceuticals & APIs

Answering Global Pharma Customers' Carbon Questions with Plant Data

Global pharmaceutical companies are asking their API, intermediate and formulation suppliers for emissions data, reduction plans and product footprints. We help Indian manufacturers build that data from batch, utility and solvent records, and design effluent systems for high-strength pharma wastewater.

Laboratory analysis in a pharmaceutical manufacturing setting

Why pharma suppliers are being asked

Large pharmaceutical companies have climate targets that include purchased goods and services, so their suppliers' emissions are part of their own numbers. Supplier programmes and industry initiatives such as the Pharmaceutical Supply Chain Initiative (PSCI) ask for energy and emissions data, targets and, increasingly, product-level footprints. In API chemistry, solvents, steam and utilities usually dominate the footprint, and effluent with high COD and dissolved solids drives treatment cost.

Coverage

Built for organizations operating in India and international markets where sustainability, carbon, and disclosure expectations need to hold up across multiple stakeholder contexts.

Scope Highlights

What We Typically Cover

Scope 1 and 2 inventory by site, with utilities (steam, chilling, compressed air) mapped to product blocks

Product carbon footprints for APIs, intermediates and formulations, including solvents and recovery

Responses to customer questionnaires and supplier sustainability platforms

ETP and ZLD design review for high-COD, high-TDS pharma effluent

Common Use Cases

Where This Work Fits Best

Customer sustainability audit or questionnaire

A global customer asks for emissions, targets and a footprint of the molecule you supply. We build the numbers and the explanation behind them.

Many products, one plant

You make dozens or hundreds of products in shared blocks. We set up an allocation method so footprints can be produced product by product without a full study each time.

Effluent treatment upgrade

Running cost or consent problems with high-strength effluent. We review segregation, treatment and ZLD options before you invest.

Delivery Outputs

What Clients Receive

The output is designed to be usable by leadership, sustainability teams, operations teams, and external-facing stakeholders without diluting the technical basis behind the work.

Site GHG inventory with documented boundaries and emission factors

Product carbon footprint method and results for priority products

Questionnaire-ready data pack and answers

Effluent treatment design basis and options review (vendor-neutral)

FAQ

Frequently Asked Questions

Is pharma covered by EU CBAM?

No. CBAM currently covers goods such as iron and steel, aluminium, cement, fertilisers, hydrogen and electricity. Pharma suppliers are asked for carbon data because of their customers' own climate targets and supplier programmes, not CBAM.

How do you calculate the footprint of one API made in a multi-product plant?

We map energy, steam, solvents and utilities to production blocks and batches, then allocate them to products using a documented method such as batch hours or mass. Raw materials and solvents are added from purchase records and recognised background data. The method is reused for other products.

Can solvent recovery reduce our footprint?

Often yes. Recovered solvent replaces virgin solvent, which usually has a significant footprint. The LCA shows how much, so you can report it credibly and decide where recovery is worth investing in.

Free resources

Relevant Sectors

API manufacturers
Intermediates
Formulations
Contract manufacturing (CDMO)
Pharma exporters